Doseology Sciences (MOOD) Price & Analysis

Compare

6 Followers

MOOD Stock Chart & Stats

C$0.53

C$0.00(0.00%)

At close: Dec 31 4:00 PM EST

C$0.53

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$0.15 - C$1.90

Previous CloseN/A

Volume0.00

Average Volume (3M)1.79K

Market Cap

C$5.05M

Enterprise ValueC$2.17M

Total Cash (Recent Filing)C$1.43M

Total Debt (Recent Filing)C$0.00

Price to Earnings (P/E)―

Beta-3.39

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding8,011,621

10 Day Avg. Volume3,383

30 Day Avg. Volume1,793

Financial Highlights & Ratios

PEG Ratio-0.49

Price to Book (P/B)3.46

Price to Sales (P/S)113.73

P/FCF Ratio-14.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clean, Low-debt Balance SheetA virtually debt-free balance sheet gives the company structural financial flexibility and lowers insolvency risk, enabling it to fund operations, R&D, or partnerships without large interest burdens. This durability matters over months as a buffer against cyclic revenue swings.

Consumer-branded Cannabinoid Product FocusA focused portfolio of dosage-controlled, functional wellness cannabinoid products targets consumer demand and supports brand-led scaling. Durable benefits include repeatable revenue channels, potential shelf/retailer placement, and differentiation versus commodity producers over a multi-month horizon.

Improving Cash Burn TrendMaterial improvement in cash burn shows management control of outflows and a path toward smaller funding needs. While cash flow remains negative, improved burn reduces near-term refinancing frequency and supports a stronger runway for executing strategic initiatives over several months.

Bears Say

Small, Volatile Revenue BaseA small and inconsistent revenue base constrains the company's ability to scale fixed costs and achieve operating leverage. Volatility undermines forecasting, weakens bargaining power with retailers, and makes multi-month planning and investment riskier for long-term growth.

Consistently Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business cannot self-fund growth and must rely on external capital. Over months this raises dilution and financing execution risk, and constrains ability to invest in marketing, distribution, or product development.

Ongoing Losses Eroding Shareholder ReturnsSustained negative returns on equity indicate the company is not generating returns from invested capital. Over time this can erode the equity base, increase the likelihood of dilutive financings, and weaken investor confidence in management's ability to reach profitability.

Doseology Sciences News

Doseology Uplists to OTCQB to Advance Growth in Oral Stimulant Pouch Market

An announcement from Doseology Sciences ( ($TSE:MOOD) ) is now available. Doseology Sciences Inc. has uplisted its common...

4d ago

Doseology debuts nicotine-free energy pouches in U.S. direct-to-consumer pilot

Doseology Sciences ( ($TSE:MOOD) ) has shared an announcement. Doseology Sciences has launched its Feed That Brain Energy...

11d ago

Doseology Taps Veteran Pharmacy Executive Larry Latowsky as Executive Chairman to Steer Commercial Expansion

Doseology Sciences ( ($TSE:MOOD) ) just unveiled an update. Doseology Sciences has appointed veteran retail and healthcare executive...

23d ago

Doseology Launches Pilot for Caffeine Energy Pouches Under Feed That Brain Brand

Doseology Sciences ( ($TSE:MOOD) ) just unveiled an update. Doseology Sciences has begun a pilot production run of...

2M ago

Doseology Boosts Transparency With New Annual Information Form Filing

Doseology Sciences ( ($TSE:MOOD) ) has issued an update. Doseology Sciences Inc. has filed its Annual Information Form...

2M ago

Doseology Taps McKinney Advisors to Fast-Track Regulatory Path for Oral Pouch Line

Doseology Sciences ( ($TSE:MOOD) ) just unveiled an announcement. Doseology Sciences has entered a strategic partnership with McKinney...

2M ago

Doseology Launches Investor Communications Initiative to Boost Market Engagement

The latest update is out from Doseology Sciences ( ($TSE:MOOD) ). Doseology Sciences Inc. has launched an Investor...

3M ago

Doseology Secures Strategic Manufacturing Agreement for Market Readiness

Doseology Sciences ( ($TSE:MOOD) ) has issued an announcement. Doseology Sciences Inc. has announced a significant milestone with...

4M ago

Doseology Sciences Expands Portfolio with Strategic Acquisition

An update from Doseology Sciences ( ($TSE:MOOD) ) is now available. Doseology Sciences Inc. has completed the acquisition...

7M ago

Doseology Acquires ‘Feed That Brain’ and Appoints Joseph Mimran as Strategic Advisor

The latest announcement is out from Doseology Sciences ( ($TSE:MOOD) ). Doseology Sciences Inc. has acquired the ‘Feed...

7M ago

MOOD FAQ

What was Doseology Sciences, Inc.’s price range in the past 12 months?

Doseology Sciences, Inc. lowest stock price was C$0.15 and its highest was C$1.90 in the past 12 months.

What is Doseology Sciences, Inc.’s market cap?

Doseology Sciences, Inc.’s market cap is C$5.05M.

When is Doseology Sciences, Inc.’s upcoming earnings report date?

Doseology Sciences, Inc.’s upcoming earnings report date is Jun 01, 2026 which is in 78 days.

How were Doseology Sciences, Inc.’s earnings last quarter?

Doseology Sciences, Inc. released its earnings results on Feb 27, 2026. The company reported -C$0.042 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.042.

Is Doseology Sciences, Inc. overvalued?

According to Wall Street analysts Doseology Sciences, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Doseology Sciences, Inc. pay dividends?

Doseology Sciences, Inc. does not currently pay dividends.

What is Doseology Sciences, Inc.’s EPS estimate?

Doseology Sciences, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Doseology Sciences, Inc. have?

Doseology Sciences, Inc. has 8,011,621 shares outstanding.

What happened to Doseology Sciences, Inc.’s price movement after its last earnings report?

Doseology Sciences, Inc. reported an EPS of -C$0.042 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Doseology Sciences, Inc.?

Currently, no hedge funds are holding shares in TSE:MOOD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Doseology Sciences, Inc.

Doseology Sciences Inc. engages in the cultivation and extraction of nutraceutical and pharmaceutical products in Canada. It focuses on research, development, and sale of medicinal mushroom products, including tinctures and powders. The company sells its products online through doseology.com. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.